A case-control study evaluating the efficacy and safety of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis.
Not Applicable
- Conditions
- Idiopathic pulmonary fibrosis
- Registration Number
- JPRN-UMIN000016045
- Lead Sponsor
- Department of Respiratory Medicine, Toho University Omori Medical Center, Tokyo,
- Brief Summary
Combination treatment with inhaled N-acetylcysteine and oral pirfenidone reduced the rate of annual FVC decline.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 27
Inclusion Criteria
Not provided
Exclusion Criteria
The exclusion criteria were (1) clinical features of idiopathic interstitial pneumonia other than IPF, (2) duration of pirfenidone therapy shorter than 1 month, due to adverse events, (3) poor adherence to inhaled NAC therapy, (4) an extent of emphysema greater than that of fibrotic change on HRCT, or physiological evidence of airflow obstruction, defined as a ratio of forced expiratory volume in 1 second (FEV1) to FVC of <0.7 or a residual volume >120%, and (5) evidence of coexisting respiratory infection or lung cancer
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method